Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ethinylestradiol, quantity: 2.7 mg; etonogestrel, quantity: 11.7 mg - drug delivery system, vaginal - excipient ingredients: magnesium stearate; vinyl acetate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; isododecane; ethylene/vinyl acetate copolymer - nuvaring is for use for contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ethinylestradiol, quantity: 2.7 mg; etonogestrel, quantity: 11.7 mg - drug delivery system, vaginal - excipient ingredients: magnesium stearate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; isododecane; ethylene/vinyl acetate copolymer; ethylene distearamide - nuvaring is for use for contraception.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - vaginal ring - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ethinylestradiol 2.7mg (15µg/24h elution rate in-vivo);  ; etonogestrel 11.7mg (120µg/24h elution rate in-vivo);   - vaginal ring - 120mcg etonogestrel, 15mcg ethinylestradiol / 24h - active: ethinylestradiol 2.7mg (15µg/24h elution rate in-vivo)   etonogestrel 11.7mg (120µg/24h elution rate in-vivo)   excipient: evatane 1020 vn3 ethylene/vinyl acetate co-polymer evatane 28-25 ethylene/vinyl acetate co-polymer magnesium stearate - contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 30 microgram; drospirenone, quantity: 3 mg - tablet - excipient ingredients: maize starch; magnesium stearate; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive

Israel - English - Ministry of Health

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - vaginal ring - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - ethinylestradiol; etonogestrel - vaginal delivery system - 2.7mg ; 11.7mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 30 microgram; levonorgestrel, quantity: 150 microgram - tablet, film coated - excipient ingredients: povidone; magnesium stearate; lactose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - oral contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.